Sofia Hambli
YOU?
Author Swipe
View article: Switch acceptance and persistence of adalimumab biosimilars in IBD patients: a prospective observational study
Switch acceptance and persistence of adalimumab biosimilars in IBD patients: a prospective observational study Open
Background: Prospective data about the acceptance and outcomes of switching from the adalimumab (ADA) reference product (RP) to multiple ADA biosimilars in inflammatory bowel disease (IBD) patients are lacking. Objectives: To evaluate the …
View article: High‐Resolution Manometry With Solid Provocative Test in Patients With Mid‐Thoracic and Epiphrenic Esophageal Diverticula
High‐Resolution Manometry With Solid Provocative Test in Patients With Mid‐Thoracic and Epiphrenic Esophageal Diverticula Open
Background The number of studies exploring esophageal motility disorders using high‐resolution manometry (HRM) in patients with esophageal diverticula (ED) is limited. The goal of this study was to describe motility disorders using HRM in …
View article: Changes Over Time in the Lémann Index and the Inflammatory Bowel Disease Disability Index in a Prospective Cohort of Patients With Crohn’s Disease
Changes Over Time in the Lémann Index and the Inflammatory Bowel Disease Disability Index in a Prospective Cohort of Patients With Crohn’s Disease Open
Background Crohn’s disease (CD) is a progressive, destructive, and disabling disorder. Our study aimed to assess changes over time in the Lémann index (LI) and the Inflammatory Bowel Disease Disability Index (IBD-DI) in a cohort of CD pati…
View article: P836 Prospective evaluation of the switch from adalimumab originator to different biosimilars in IBD patients : acceptability and persistance at 1 year
P836 Prospective evaluation of the switch from adalimumab originator to different biosimilars in IBD patients : acceptability and persistance at 1 year Open
Background The use of biological therapies represents a major source of direct healthcare costs for inflammatory bowel disease (IBD) in industrialised countries. Several adalimumab (ADA) biosimilars are available for Crohn's disease (CD) a…
View article: P377 Changes over time in the Lémann Index and the Inflammatory Bowel Disease-Disability Index in patients with Crohn’s disease
P377 Changes over time in the Lémann Index and the Inflammatory Bowel Disease-Disability Index in patients with Crohn’s disease Open
Background Crohn’s disease (CD) is a progressive, transmural disorder that leads to intestinal damage (fistula, abscesses, stenosis) and worsens the patient’s quality of life. The Lémann Index (LI, assessing cumulative bowel damage in CD) …
View article: P458 Association between adalimumab serum levels and level of remission in Crohn’s disease
P458 Association between adalimumab serum levels and level of remission in Crohn’s disease Open
Background Adalimumab (ADA) is effective as induction and maintenance therapy in Crohn’s disease (CD). Serum ADA levels have been shown to be correlated with clinical remission. Therapeutic goals have evolved based on the notion of ‘treat …